Retroviral expression of a kinase-defective IGF-I receptor suppresses growth and causes apoptosis of CHO and U87 cells in-vivo
© Seely et al; licensee BioMed Central Ltd. 2002
Received: 18 April 2002
Accepted: 31 May 2002
Published: 31 May 2002
Phosphatidylinositol-3,4,5-triphosphate (PtdInsP3) signaling is elevated in many tumors due to loss of the tumor suppressor PTEN, and leads to constitutive activation of Akt, a kinase involved in cell survival. Reintroduction of PTEN in cells suppresses transformation and tumorigenicity. While this approach works in-vitro, it may prove difficult to achieve in-vivo. In this study, we investigated whether inhibition of growth factor signaling would have the same effect as re-expression of PTEN.
Dominant negative IGF-I receptors were expressed in CHO and U87 cells by retroviral infection. Cell proliferation, transformation and tumor formation in athymic nude mice were assessed.
Inhibition of IGF-IR signaling in a CHO cell model system by expression of a kinase-defective IGF-IR impairs proliferation, transformation and tumor growth. Reduction in tumor growth is associated with an increase in apoptosis in-vivo. The dominant-negative IGF-IRs also prevented growth of U87 PTEN-negative glioblastoma cells when injected into nude mice. Injection of an IGF-IR blocking antibody αIR3 into mice harboring parental U87 tumors inhibits tumor growth and increases apoptosis.
Inhibition of an upstream growth factor signal prevents tumor growth of the U87 PTEN-deficient glioma to the same extent as re-introduction of PTEN. This result suggests that growth factor receptor inhibition may be an effective alternative therapy for PTEN-deficient tumors.
Phosphatidylinositol-(3,4,5)-trisphosphate (PIP3) is one of the major intracellular second messengers regulating growth, metabolism and vesicular trafficking [for reviews see refs [1–3]]. The level of (PIP3) in the cell is determined by the balance of kinase and phosphatase activity. PI-3Kinase activity is acutely regulated and a number of isoforms have been cloned that are activated in response to various stimuli . The major phosphatidylinositol-3-phosphate phosphatase in cells is the tumor suppressor PTEN [5, 6]. This protein has a tonic inhibitory effect on PI-3Kinase signaling by reversing the 3'-phosphorylation. PTEN is altered or deleted in many human cancers [7–10]. In-vitro, cells that are deficient in PTEN show elevated PI-3Kinase signaling . Reintroduction of PTEN in a variety of cancer cells, including glioma, breast, bladder and ovarian cancer cells, causes G1 arrest, inhibits tumorigenesis, and promotes anoikis [12–14]. Mechanistically, Akt activity is decreased, cell motility is decreased, expression of two cyclin-dependent kinase inhibitors p27 and p21 is increased, cyclin D1 is down-regulated, Rb phosphorylation is inhibited, and signaling via Grb2/SOS is suppressed [11, 15]. The link between PTEN and cell growth is underscored by genetic experiments in mice. PTEN knockout mice die in-utero due to extensive overgrowth of the cephalic and caudal regions [12, 16]. PTEN +/- heterozygous mice have a predisposition to tumors in multiple tissues often with loss of the second allele [17, 18]. In-vitro, PTEN-/- embryonic stem cells and fibroblasts display increased proliferation and decreased sensitivity to apoptosis.
The PI-3Kinase-dependent activation of Akt is thought to play a central role in the cell survival pathway in many cells [7, 19, 20]. Elevated Akt activity and protein is found in many PTEN-deficient cancer cells. Akt directly phosphorylates and inactivates the pro-apoptotic proteins ASK1, BAD, caspase 9 [21–24]. Akt also induces the expression of the anti-apoptotic Bcl-2 and c-FLIP proteins, and suppresses the cell cycle inhibitor p27KIP[25–28]. This later effect is via the phosphorylation and inactivation of the forkhead family of transcription factors AFX, FKHR and FKHR-L1. Although it is often assumed that elevated Akt activity is responsible for the increased survival of cancer cells, Akt activity is not the only pathway that is essential for cell survival. The MAPK pathway can also protect cells from apoptosis, as can constitutive activation of Stat3 signaling [29, 30].
The IGF-I Receptor is a member of the large family of tyrosine kinase growth factor receptors. Signaling by the IGF-IR has been studied in many different cell types and is important for proliferation, survival, motility, adhesion, transformation, tumor formation and metastasis [for reviews see refs [31, 32]]. The receptor can directly phosphorylate the insulin receptor substrate 1 (IRS-1) and Shc proteins in the intact cell causing activation of PI-3Kinase and ras signaling . More recently, it has been shown that the IGF-IR signals via the Gβγ subunits of the heterotrimeric Gi complex to stimulate PI-3Kinase and ras, and also activates the JAK/Stat pathway to cause phosphorylation of Stat3 [34, 35].
What is the evidence for the involvement of IGF-IR signaling in proliferation and cancer? Elegant studies in knockout mice have delineated the contribution of IGF-I, IGF-II and the IGF-I receptor to fetal growth [for review see ref ]. Embryonic fibroblasts derived from IGF-IR knockout embryos (R-cells) do not grow in serum-free medium, despite supplementation with a wide variety of other growth factors, and grow more slowly in media containing serum than wild-type cells [for reviews see refs [37, 38]]. Additionally, all phases of the cell cycle are prolonged in the null cells suggesting that the IGF-IR is required throughout the cell cycle. A functional IGF-I receptor is required for successful cell transformation. IGF-IR-/- cells are not transformed by overexpression of SV40 T antigen, activated ras, or EGF or PDGF receptors. Transformation appears to involve autocrine stimulation as IGF-I production and secretion is increased in normal cells following transformation by SV40 T antigen, but the null cells cannot respond to the IGF-I so do not transform.
Interfering with the IGF signaling system can inhibit the growth of cancer cells in-vitro and in-vivo. Treatment with antagonistic peptide analogs of IGF-I, antisense oligos, or an adenovirus expressing IGF-IR antisense cRNA, prevents proliferation of cells in monolayers, transformation, and growth in athymic nude mice. This includes multiple human tumor cell lines including glioblastoma, melanoma, ovarian carcinoma, prostatic carcinoma, and breast carcinomas). [for reviews see refs ,[39–41]]. The IGF-IR appears to function in transformation both by preventing apoptosis through activation of Akt and by stimulating proliferation through the ras-MAPK cascade. IGF-I can prevent c-myc-induced apoptosis in rat-l fibroblasts, and neuronal apoptosis due to serum-starvation. IGF-IR-/- cells can proliferate in monolayers in the presence of serum but undergo apoptosis when put in suspension and are more sensitive to chemotherapeutic reagents. There is also evidence implicating the IGF-IR in metastasis. IGF-I produces a chemotactic response in human melanoma cells and antisense to the IGF-IR mRNA prevents metastasis in the murine carcinoma cell H-59.
In this study, we wanted to determine if disruption of IGF-I signaling could prevent growth of a tumor cell lacking PTEN. Elevated PI-3Kinase can be normalized by reintroduction of PTEN to reduce PIP3 levels, but it has not been shown that this effect can also be achieved by disruption of an upstream signal that stimulates PI-3Kinase activity. We have previously demonstrated the overexpression and hormone-independent activation of the IGF-IR in primary breast cancers . Similar overexpression of the IGF-IR and the ligands IGF-I and IGF-II have been seen in human gliomas and astrocytomas [43–46]. Because of the important role for the IGF-IR in cell survival, we investigated whether a dominant negative IGF-IR could inhibit growth of the U87 glioma. This glioma is deficient in PTEN and shows constitutive activation of Akt, which can be inactivated by re-introduction of PTEN .
Materials and Methods
Materials and Cell Culture
Antiphosphotyrosine antibodies (pY20) were from BD-Transduction Labs (Lexington, KY). Matrigel was from Becton-Dickinson (Bedford, MA) Athymic nude mice were purchased from Charles River (Wilmington, MA). Enhanced chemiluminescence reagents were from Amersham (Piscataway, NJ). [3H]-thymidine (20 Ci/mmol) was from Perkin-Elmer/NEN Life Sciences (Boston, MA). Unless noted, all other reagents were supplied by Sigma Chemical Co. (St. Louis, MO) or Fisher Scientific Co. (Springfield, NJ). CHO cells were maintained in Hams F12 with 25 mM glucose with 50 units/ml penicillin, 50 μg/ml streptomycin, and 10% FCS in a 10 % CO2 environment. U87 glioma cells were maintained in MEM-Earle's medium with non-essential amino acids, 1 mM sodium pyruvate, 10% FCS, 2 mM Glutamax and gentamycin sulphate in a 10% CO2 environment.
Cells were serum starved for 16 h in 12-well plates, then stimulated with IGF-I (10 or 100 ng/ml) for 5 min at 37°C. The cells were washed with ice-cold phosphate-buffered saline and solubilized in 2 × SDS-sample buffer containing 2 mM sodium orthovanadate and 200 mM sodium fluoride. The proteins were denatured by boiling for 5 min, then were separated by electrophoresis on 7.5% SDS-PAGE, and transferred to PVDF membranes. The filter was blocked with 3% BSA in TBS with 0.1% Tween 20 (T-TBS) for 30 min and incubated with the anti-phosphotyrosine antibodies at a dilution of 1:1000. The filters were washed with T-TBS for 30 min and incubated with horseradish-peroxidase conjugated secondary antibodies, and tyrosine-phosphorylated proteins were visualized by enhanced chemiluminescence.
Measurement of thymidine incorporation
Cells were grown to 75% confluence in six-well cluster plates. The growth medium was replaced with serum-free Ham's F12 for 36 h. Cells were stimulated with IGF-I at the indicated concentrations for 18 h. Cells were pulsed with [3H]-thymidine, 2 μCi/ml, for 1 h at 37°C. The cells were washed five times in PBS, solubilized, the DNA precipitated with 10% trichloroacetic acid at 4°C, and counted in an scintillation counter.
Production of pseudo-typed retrovirus
The wild-type IGF-IR cDNA or a mutant cDNA, which contained a methionine substitution for lysine 1003 in the ATP-binding site of the kinase domain, were cloned into the retroviral vector pLPONL . The pseudo-typed viruses were generated and purified by the UCSD Viral Vector Core. The plasmids were co-transfected into 293 cells with an expression vector for the Vesicular Stomatitis Virus-G protein. This coat protein allows the virus to be concentrated and confers greater tropism. Cell culture supernatants and cells were harvested and the virus concentrated. Viruses were titered on NIH3T3 cells and the number of G418 resistant colonies counted. A control virus containing the E. coli β-galactosidase gene was obtained from the Viral Vector Core.
Growth in Soft Agar
Cells were trypsinized and 104 cells plated in 35 mm petri dishes in complete medium containing 0.35% agarose over a layer of 0.7% agarose in complete medium. Cells were allowed to grow for 14–21 days or until colonies were >125 μm in diameter. Fresh medium was layered above the agarose every 3–5 days. Colonies were stained with Crystal Violet and counted.
Tumor Growth in Athymic Nude Mice
Housing and all procedures using nude mice were approved by the animal care committee at UCSD. The cells for injection were trypsinized in sterile PBS, pelleted by centrifugation at 300 × g for 2 min. and washed twice in sterile saline. Cells were resuspended in 100 μl sterile saline and counted using a hemacytometer. The appropriate number of cells was diluted into 50 μl sterile saline and then added to an equal volume of sterile Matrigel on ice. This suspension was injected subcutaneously on the rear flank of athymic nude mice using a sterile syringe and 22-gauge needle. Mice were observed on a twice-weekly basis to check for tumor growth. Tumors were measured with calipers in three dimensions and tumor volume calculated assuming the tumors were ellipsoid. At the end of the study, the tumors were excised, measured, weighed, and then fixed in 10% formalin. Tumors were embedded in paraffin, sectioned and stained with hematoxylin-eosin or for apoptosis using the TUNEL assay (Roche, Indianapolis, IN).
Results and Discussion
Inhibition of the IGF-I receptor by expression of a kinase inactive mutant inhibits proliferation of Chinese hamster ovary (CHO) cells
Before embarking on studies in human tumor cells, we verified that our dominant negative approach would work in a model system. To inhibit the IGF-IR, we took advantage of the fact that the IGF-I receptor is a hetero-tetramer. Activation of the native receptor requires the trans-phosphorylation of two kinase domains . Hence, expression of an excess of kinase-defective IGF-I receptors causes the formation of hybrid molecules containing one half an endogenous wild-type receptor and the other half a kinase-defective transfected receptor. These hybrids should be kinase inactive and signaling incompetent. Similar approaches have been used successfully in other studies [49–52].
Initially, we tested Chinese hamster ovary (CHO) cells that had been stably transfected with expression vectors for kinase-inactive or wild type IGF-I receptors . The parental CHO cell line expresses ~50,000 endogenous IGF-IRs, the transfected wild-type (CHO-WT) cell line expresses ~250,000 IGF-IRs, and the kinase-defective (CHO-MK) cell line expresses ~250,000 mutant IGF-IRs. Thus, the transfected cells express the human IGF-IR at approximately five fold higher levels than the endogenous receptor. The mutant receptor contains a lysine to methionine (MK) point mutation at position 1003 in the ATP binding site of the kinase domain and has no measurable kinase activity. Two clonal lines expressing the MK receptor were used with identical results.
We then tested colony formation in soft agar as an indicator of cellular transformation. Cells were trypsinized, counted and equivalent numbers of cells plated in soft agar in complete medium. Cells were cultured for 14 – 21 days and then the number of colonies counted. Overexpression of the wild-type IGF-IRs increased the number of colonies, and overexpressing the kinase-defective receptors reduced the number of colonies by 60% (Figure 1C). Not only did we observe a difference of the number of colonies, but CHO-MK colonies were smaller than either the parental CHO or CHO-WT colonies (data not shown).
We next studied the ability of each of these cell lines to form tumors in athymic nude mice. Ten million (107) cells from each cell line were injected subcutaneously into the flanks of five athymic nude mice. Tumor size was measured biweekly. The mice were euthanized at the end of three weeks and the tumors excised and weighed (Figure 1D &1E). At this high level of innoculum, there was no difference in tumor incidence (data not shown). However, expression of the wild-type IGF-IR accelerated tumor growth and tumors were larger at sacrifice. The kinase defective IGF-IR, on the other hand, delayed the appearance of tumors and smaller tumors were found at sacrifice.
An inhibitory antibody to the IGF-IR inhibits growth of U87 tumors
Effect of antibody αIR3 on transformation and tumor growth.
Colonies in soft agar
28 ± 3
11 ± 2
27 ± 2
Tumors in nude mice
Retroviral expression of the kinase inactive IGF-I Receptor inhibits growth of U87 glioblastoma cells in-vivo
To make expression of kinase defective IGF-I receptors in different cell lines more tractable, we generated pseudotyped retroviruses expressing either the kinase-defective (MK) or wild-type (WT) IGF-I receptors. We also obtained a virus expressing the beta-galactosidase (LacZ) protein to measure infection efficiency and serve as a virus control. U87 cells were infected with the MK, WT or LacZ viruses and selected with G418. Pools of cells containing stably integrated retroviruses were then used in transformation and tumor growth experiments. Binding studies showed that the U87-LacZ cells express 105 endogenous IGF-IRs per cell, while the U87-WT and U87-MK cells express 3 × 106 and 2 × 106 receptors per cells respectively. Thus, the retrovirus allows 20 to 30-fold overexpression of the transfected receptor.
Growth of infected U87 cells in nude mice.
5 × 105
0.48 ± 0.11
0.67 ± 0.15
0.13* ± 0.02
0.43 ± 0.13
0.57 ± 0.1
0.12* ± 0.02
The idea that the IGF-IR might be a valuable target for the treatment of brain tumors is supported by a recent pilot study in twelve patients with malignant astrocytomas . All patients had grade 3 or 4 astrocytomas and had failed on standard therapy. The PTEN status of their primary tumors was not known. After surgery, autologous glioma cells were collected and treated ex-vivo with IGF-IR antisense oligos and re-implanted in diffusion chambers for 24 h. Clinical and radiological improvements were seen in eight of the twelve patients. Five patients showed a lymphocytic infiltration after antisense treatment indicating that knocking out the IGF-IR induced an immune response. It would be interesting to determine whether response to this treatment correlated with loss of PTEN in the primary tumors.
Loss of PTEN is a very common occurrence in human tumors. Restoring PTEN protein or function to reduce PI-3Kinase signaling prevents tumor growth in animal models. However, it may not be possible to restore PTEN in human tumors. Direct inhibition of PI-3Kinase activity may not be feasible either as it is likely to have severe side effects. Our results suggest that a therapeutic strategy to inhibit the upstream stimulus for PI-3Kinase through blockade of growth factor receptors may provide a workable alternative.
B.L.S. conducted the studies on CHO cells and the inhibitory antibody studies on U87 cells. G.S. performed the tumor growth studies with the U87 cells. N.J.G.W. constructed the pseudotyped retroviruses and drafted the manuscript.
Dulbecco's Modified Eagle's Medium
mitogen-activated protein kinase
insulin-like growth factor
phosphatase and tensin homolog deleted from chromosome 10
son-of-sevenless ras exchange factor
apoptosis stimulating kinase
forkhead related protein
cellular FLICE interacting protein
bovine serum albumin
tris buffered saline
This research was supported by a NIH Clinical Investigator Award (to B.L.S.) and a CapCURE award (to N.J.G.W.). We would like to acknowledge the expert technical assistance of Donna Reichart. N.J.G.W. is a faculty member of the UCSD Biomedical Sciences Graduate Program. B.L.S. current address is ProDuct Health Inc., Menlo Park, CA.
- Rameh LE, Cantley LC: The role of phosphoinositide 3-kinase lipid products in cell function. J Biol Chem. 1999, 274: 8347-8350. 10.1074/jbc.274.13.8347.View ArticlePubMedGoogle Scholar
- Katso R, Okkenhaug K, Ahmadi K, White S, Timms J, Waterfield MD: Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer. Annu Rev Cell Dev Biol. 2001, 17: 615-675. 10.1146/annurev.cellbio.17.1.615.View ArticlePubMedGoogle Scholar
- Cantrell DA: Phosphoinositide 3-kinase signalling pathways. J Cell Sci. 2001, 114: 1439-1445.PubMedGoogle Scholar
- Vanhaesebroeck B, Waterfield MD: Signaling by distinct classes of phosphoinositide 3-kinases. Exp Cell Res. 1999, 253: 239-254. 10.1006/excr.1999.4701.View ArticlePubMedGoogle Scholar
- Leslie NR, Downes CP: PTEN: The down side of PI 3-kinase signalling. Cellular Signalling. 2002, 14: 285-295. 10.1016/S0898-6568(01)00234-0.View ArticlePubMedGoogle Scholar
- Maehama T, Dixon JE: PTEN: a tumour suppressor that functions as a phospholipid phosphatase. Trends Cell Biol. 1999, 9: 125-128. 10.1016/S0962-8924(99)01519-6.View ArticlePubMedGoogle Scholar
- Cantley LC, Neel BG: New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci U S A. 1999, 96: 4240-4245. 10.1073/pnas.96.8.4240.View ArticlePubMedPubMed CentralGoogle Scholar
- Liaw D, Marsh DJ, Li J, Dahia PL, Wang SI, Zheng Z, et al: Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet. 1997, 16: 64-67.View ArticlePubMedGoogle Scholar
- Ali IU, Schriml LM, Dean M: Mutational spectra of PTEN/MMAC1 gene: a tumor suppressor with lipid phosphatase activity. J Natl Cancer Inst. 1999, 91: 1922-1932. 10.1093/jnci/91.22.1922.View ArticlePubMedGoogle Scholar
- Dahia PL: PTEN, a unique tumor suppressor gene. Endocr Relat Cancer. 2000, 7: 115-129.View ArticlePubMedGoogle Scholar
- Davies MA, Koul D, Dhesi H, Berman R, McDonnell TJ, McConkey D, et al: Regulation of Akt/PKB activity, cellular growth, and apoptosis in prostate carcinoma cells by MMAC/PTEN. Cancer Res. 1999, 59: 2551-2556.PubMedGoogle Scholar
- Di Cristofano A, Pandolfi PP: The multiple roles of PTEN in tumor suppression. Cell. 2000, 100: 387-390.View ArticlePubMedGoogle Scholar
- Yamada KM, Araki M: Tumor suppressor PTEN: modulator of cell signaling, growth, migration and apoptosis. J Cell Sci. 2001, 114: 2375-2382.PubMedGoogle Scholar
- Teng DH, Hu R, Lin H, Davis T, Iliev D, Frye C, et al: MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines. Cancer Res. 1997, 57: 5221-5225.PubMedGoogle Scholar
- Ramaswamy S, Nakamura N, Vazquez F, Batt DB, Perera S, Roberts TM, et al: Regulation of G1 progression by the PTEN tumor suppressor protein is linked to inhibition of the phosphatidylinositol 3-kinase/Akt pathway. Proc Natl Acad Sci U S A. 1999, 96: 2110-2115. 10.1073/pnas.96.5.2110.View ArticlePubMedPubMed CentralGoogle Scholar
- Suzuki A, de la Pompa JL, Stambolic V, Elia AJ, Sasaki T, del Barco Barrantes I, et al: High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice. Curr Biol. 1998, 8: 1169-1178. 10.1016/S0960-9822(07)00488-5.View ArticlePubMedGoogle Scholar
- Stambolic V, Tsao MS, Macpherson D, Suzuki A, Chapman WB, Mak TW: High incidence of breast and endometrial neoplasia resembling human Cowden syndrome in pten+/- mice. Cancer Res. 2000, 60: 3605-3611.PubMedGoogle Scholar
- Podsypanina K, Ellenson LH, Nemes A, Gu J, Tamura M, Yamada KM, et al: Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proc Natl Acad Sci U S A. 1999, 96: 1563-1568. 10.1073/pnas.96.4.1563.View ArticlePubMedPubMed CentralGoogle Scholar
- Testa JR, Bellacosa A: AKT plays a central role in tumorigenesis. PNAS. 2001, 98: 10983-10985. 10.1073/pnas.211430998.View ArticlePubMedPubMed CentralGoogle Scholar
- Datta SR, Brunet A, Greenberg ME: Cellular survival: a play in three Akts. Genes Dev. 1999, 13: 2905-2927. 10.1101/gad.13.22.2905.View ArticlePubMedGoogle Scholar
- Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, et al: Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell. 1997, 91: 231-241. 10.1016/S0092-8674(00)80405-5.View ArticlePubMedGoogle Scholar
- del Peso L, Gonzalez-Garcia M, Page C, Herrera R, Nunez G: Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science. 1997, 278: 687-689. 10.1126/science.278.5338.687.View ArticlePubMedGoogle Scholar
- Kim AH, Khursigara G, Sun X, Franke TF, Chao MV: Akt phosphorylates and negatively regulates apoptosis signal-regulating kinase 1. Mol Cell Biol. 2001, 21: 893-901. 10.1128/MCB.21.3.893-901.2001.View ArticlePubMedPubMed CentralGoogle Scholar
- Cardone MH, Roy N, Stennicke HR, Salvesen GS, Franke TF, Stanbridge E, et al: Regulation of cell death protease caspase-9 by phosphorylation. Science. 1998, 282: 1318-1321. 10.1126/science.282.5392.1318.View ArticlePubMedGoogle Scholar
- Cheney IW, Neuteboom ST, Vaillancourt MT, Ramachandra M, Bookstein R: Adenovirus-mediated gene transfer of MMAC1/PTEN to glioblastoma cells inhibits S phase entry by the recruitment of p27Kip1 into cyclin E/CDK2 complexes. Cancer Res. 1999, 59: 2318-2323.PubMedGoogle Scholar
- Weng LP, Brown JL, Eng C: PTEN coordinates G(1) arrest by down-regulating cyclin D1 via its protein phosphatase activity and up-regulating p27 via its lipid phosphatase activity in a breast cancer model. Hum Mol Genet. 2001, 10: 599-604. 10.1093/hmg/10.6.599.View ArticlePubMedGoogle Scholar
- Winter RN, Kramer A, Borkowski A, Kyprianou N: Loss of Caspase-1 and Caspase-3 Protein Expression in Human Prostate Cancer. Cancer Res. 2001, 61: 1227-1232.PubMedGoogle Scholar
- Pugazhenthi S, Nesterova A, Sable C, Heidenreich KA, Boxer LM, Heasley LE, et al: Akt/protein kinase B up-regulates Bcl-2 expression through cAMP-response element-binding protein. J Biol Chem. 2000, 275: 10761-10766. 10.1074/jbc.275.15.10761.View ArticlePubMedGoogle Scholar
- Scrimgeour AG, Blakesley VA, Stannard BS, LeRoth D: Mitogen-activated protein kinase and phosphatidylinositol 3-kinase pathways are not sufficient for insulin-like growth factor I-induced mitogenesis and tumorigenesis. Endocrinology. 1997, 138: 2552-2558. 10.1210/en.138.6.2552.View ArticlePubMedGoogle Scholar
- Ni Z, Lou W, Leman ES, Gao AC: Inhibition of Constitutively Activated Stat3 Signaling Pathway Suppresses Growth of Prostate Cancer Cells. Cancer Res. 2000, 60: 1225-1228.PubMedGoogle Scholar
- Baserga R: The IGF-I receptor in cancer research. Exp Cell Res. 1999, 253: 1-6. 10.1006/excr.1999.4667.View ArticlePubMedGoogle Scholar
- LeRoith D, Baserga R, Helman L, Roberts CT: Insulin-like growth factors and cancer. Ann Intern Med. 1995, 122: 54-59.View ArticlePubMedGoogle Scholar
- LeRoith D, Werner H, Beitner-Johnson D, Roberts CTJ: Molecular and cellular aspects of the insulin-like growth factor I receptor. Endocr. Rev. 1995, 16: 143-163. 10.1210/er.16.2.143.View ArticlePubMedGoogle Scholar
- Luttrell LM, Van Biesen T, Hawes BE, Koch WJ, Touhara K, Lefkowitz RJ: G beta gamma subunits mediate mitogen-activated protein kinase activation by the tyrosine kinase insulin-like growth factor 1 receptor. J. Biol. Chem. 1995, 270: 16495-16498. 10.1074/jbc.270.28.16495.View ArticlePubMedGoogle Scholar
- Zong CS, Zeng L, Jiang Y, Sadowski HB, Wang LH: Stat3 plays an important role in oncogenic Ros- and insulin-like growth factor I receptor-induced anchorage-independent growth. J Biol Chem. 1998, 273: 28065-28072. 10.1074/jbc.273.43.28065.View ArticlePubMedGoogle Scholar
- Accili D, Nakae J, Kim JJ, Park BC, Rother KI: Targeted gene mutations define the roles of insulin and IGF-I receptors in mouse embryonic development. J Pediatr Endocrinol Metab. 1999, 12: 475-485.View ArticlePubMedGoogle Scholar
- Baserga R: The insulin-like growth factor I receptor: a key to tumor growth?. Cancer Res. 1995, 55: 249-252.PubMedGoogle Scholar
- Baserga R, Hongo A, Rubini M, Prisco M, Valentinis B: The IGF-I receptor in cell growth, transformation and apoptosis. Biochim Biophys Acta. 1997, 1332: F105-126. 10.1016/S0304-419X(97)00007-3.PubMedGoogle Scholar
- Baserga R, Resnicoff M, Dews M: The IGF-I receptor and cancer. Endocrine. 1997, 7: 99-102.View ArticlePubMedGoogle Scholar
- Pollak M, Beamer W, Zhang JC: Insulin-like growth factors and prostate cancer. Cancer Metastasis Rev. 1999, 17: 1998-383.Google Scholar
- Yee D: The insulin-like growth factor system as a target in breast cancer. Breast Cancer Res. Treat. 1994, 32: 85-95.View ArticlePubMedGoogle Scholar
- Resnik JL, Reichart DB, Huey K, Webster NJ, Seely BL: Elevated insulin-like growth factor I receptor autophosphorylation and kinase activity in human breast cancer. Cancer Res. 1998, 58: 1159-1164.PubMedGoogle Scholar
- Ogino S, Kubo S, Abdul-Karim FW, Cohen ML: Comparative immunohistochemical study of insulin-like growth factor II and insulin-like growth factor receptor type 1 in pediatric brain tumors. Pediatr Dev Pathol. 2001, 4: 23-31. 10.1007/s100240010112.View ArticlePubMedGoogle Scholar
- Antoniades HN, Galanopoulos T, Neville-Golden J, Maxwell M: Expression of insulin-like growth factors I and II and their receptor mRNAs in primary human astrocytomas and meningiomas; in vivo studies using in situ hybridization and immunocytochemistry. Int J Cancer. 1992, 50: 215-222.View ArticlePubMedGoogle Scholar
- Gammeltoft S, Ballotti R, Nielsen FC, Kowalski A, Van Obberghen E: Receptors for insulin-like growth factors in the central nervous system: structure and function. Horm Metab Res. 1988, 20: 436-442.View ArticlePubMedGoogle Scholar
- Sandberg AC, Engberg C, Lake M, von Holst H, Sara VR: The expression of insulin-like growth factor I and insulin-like growth factor II genes in the human fetal and adult brain and in glioma. Neurosci Lett. 1988, 93: 114-119. 10.1016/0304-3940(88)90022-5.View ArticlePubMedGoogle Scholar
- Wick W, Furnari FB, Naumann U, Cavenee WK, Weller M: PTEN gene transfer in human malignant glioma: sensitization to irradiation and CD95L-induced apoptosis. Oncogene. 1999, 18: 3936-3943. 10.1038/sj.onc.1202774.View ArticlePubMedGoogle Scholar
- Lammers R, Van Obberghen E, Ballotti R, Schlessinger J, Ullrich A: Transphosphorylation as a possible mechanism for insulin and epidermal growth factor receptor activation. J. Biol. Chem. 1990, 265: 16886-16890.PubMedGoogle Scholar
- Treadway JL, Morrison BD, Soos MA, Siddle K, Olefsky J, Ullrich A, et al: Transdominant inhibition of tyrosine kinase activity in mutant insulin/insulin-like growth factor I hybrid receptors. Proc. Natl. Acad. Sci. U.S.A. 1991, 88: 214-218.View ArticlePubMedPubMed CentralGoogle Scholar
- Seely BL, Reichart DR, Takata Y, Yip C, Olefsky JM: A functional assessment of insulin/insulin-like growth factor-I hybrid receptors. Endocrinology. 1995, 136: 1635-1641. 10.1210/en.136.4.1635.PubMedGoogle Scholar
- Kalebic T, Blakesley V, Slade C, Plasschaert S, Leroith D, Helman LJ: Expression of a kinase-deficient IGF-I-R suppresses tumorigenicity of rhabdomyosarcoma cells constitutively expressing a wild type IGF-I-R. Int J Cancer. 1998, 76: 223-227. 10.1002/(SICI)1097-0215(19980413)76:2<223::AID-IJC9>3.0.CO;2-Z.View ArticlePubMedGoogle Scholar
- Burgaud JL, Resnicoff M, Baserga R: Mutant IGF-I receptors as dominant negatives for growth and transformation. Biochem. Biophys. Res. Commun. 1995, 214: 475-481. 10.1006/bbrc.1995.2311.View ArticlePubMedGoogle Scholar
- Hsu D, Knudson PE, Zapf A, Rolband GC, Olefsky JM: NPXY motif in the insulin-like growth factor-I receptor is required for efficient ligand-mediated receptor internalization and biological signaling. Endocrinology. 1994, 134: 744-750. 10.1210/en.134.2.744.PubMedGoogle Scholar
- Cheney IW, Johnson DE, Vaillancourt MT, Avanzini J, Morimoto A, Demers GW, et al: Suppression of tumorigenicity of glioblastoma cells by adenovirus-mediated MMAC1/PTEN gene transfer. Cancer Res. 1998, 58: 2331-2334.PubMedGoogle Scholar
- Arteaga CL, Kitten LJ, Coronado EB, Jacobs S, Kull FC, Allred DG, et al: Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice. J Clin Invest. 1989, 84: 1418-1423.View ArticlePubMedPubMed CentralGoogle Scholar
- Andrews DW, Resnicoff M, Flanders AE, Kenyon L, Curtis M, Merli G, et al: Results of a Pilot Study Involving the Use of an Antisense Oligodeoxynucleotide Directed Against the Insulin-Like Growth Factor Type I Receptor in Malignant Astrocytomas. J Clin Oncol. 2001, 19: 2189-2200.PubMedGoogle Scholar
- Friedmann T, Yee JK: Pseudotyped retroviral vectors for studies of human gene therapy. Nat. Med. 1995, 1: 275-277.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/2/15/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.